After months of searching for strategic options, Adaptimmune is offloading its cell therapies to a global pharma, which plans to offer jobs to about half of the biotech’s employees. Once the deal closes, Adaptimmune will reduce its remaining workforce by 62%.
https://www.fiercebiotech.com/biotech/adaptimmune-sells-4-cell-therapies-pharma-55m-plans-layoffs